Overall Survival

Progression-Free-Survival

Variables

     HR          95%CI           P-value

     HR          95%CI        P-value

Age > 60 years

   1.111   1.024-1.428      <0.008

 

Extra nodal sites-R > 1

   1.090   0.918-1.285       0.8

   1.235    0.809-1.168       0.4

LDH

   1.000   0.999-1.007       0.7

   1.050    1.000-1.232      0.07

LDH-R

   1.523   1.001-1.812    <0.05

   1.204    0.838-1.408      0.7

IPI ≥ 2

   1.039   0.962-1.935       0.8

   1.035    0.965-1.672      0.4

IPI-R > 2

   1.178   0.849-1.308       0.6

   1.354    0.738-1.944      0.2

CR prior to transplant

  0.679   0.472-1.001       0.1

   0.656    0.572-1.001      0.07

ALC-15 ≥ 500 cells/µl

   0.424   0.236-0.617     <0.0004

   0.608   0.466-0.804     <0.02

AMC-15 ≥ 600 cell/µl

  2.177    1.459-2.861     <0.002

   1.525   1.000-1.904       0.06

ALC/AMC-15 ratio ≥ 1

  0.220    0.089-0.540      <0.0001

   0.171  0.115-0.349      <0.0001

ANC-15

  0.915    0.904-1.003         0.2

   0.916  0.812-1.021         0.1

Plts-15

  0.999    0.994-1.004         0.7

   0.999  0.994-1.003         0.7

PS-R > 1

  1.043    0.589-1.958         0.9

   1.011  0.988-1.168         0.9

Stage-R III/IV

  1.597    1.086-1.918      <0.04

   1.449  0.999-1.973         0.07

Pre-transplant Rituximab

  0.522    0.409-0.906      <0.01

   0.845  0.582-1.190         0.5


Abbreviations: Age-R = age at relapse; Extranodal sites-R = extranodal sites at relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse; PS = performance status; PS-R = performance status at relapse; stage-r = stage at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic Index at relapse; CR = complete remission; PR = partial response; ALC = absolute lymphocyte count; ANC-15 = absolute neutrophil count at day 15; AMC = absolute monocyte count; and plts-15 = platelets at day 15
Table 4: Multivariate analysis for Overall Survival and Progression-Free Survival.